|

Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse

RECRUITINGN/ASponsored by Rennes University Hospital
Actively Recruiting
PhaseN/A
SponsorRennes University Hospital
Started2025-03-22
Est. completion2035-04
Eligibility
Age0 Years – 17 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06649253

Summary

B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.

Eligibility

Age: 0 Years – 17 YearsHealthy volunteers accepted
Inclusion Criteria:

* Under 18 years
* With established diagnosis of B-ALL
* Initial diagnosis made in the investigating centre
* Having received oral and written information about the protocol, or oral only if the patient is unable to read.
* Having signed a consent form if the patient is capable of giving informed written consent.
* Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent.
* Beneficiary of a social security scheme

Exclusion Criteria:

* Isolated extramedullary involvement at inclusion
* Patient of childbearing age without effective contraception.
* Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.

Conditions2

CancerLeukemia, Lymphoblastic, Acute, Pediatric

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.